I don"t know for certain if there was any ad- hoc studies done in the boceprevir trials according to the different alleles,however there was one done in the Telapravir trials and there was a significant improvement on success rates for both the CT and TT alleles over and above the success with doing just Interferon and Riba.
Good luck with your upcoming treatment.
Will.
In the boceprevir-containing arms of SPRINT-2, 80% to 82% of patient with the CC genotype achieved SVR. Importantly, nearly 90% of patients with the CC genotype were eligible for shorter duration of therapy (28 weeks). Thus, although CC patients may not achieve higher SVR rates with boceprevir combination therapy vs pegIFN/RBV alone for 48 weeks, the advantage is that the majority qualify for shorter therapy (28 weeks). Boceprevir substantially improved SVR rates for patients with the CT and TT genotypes: SVR rates were 71% and 59% for CT and TT genotype patients in the BOC + PR48 arm and 65% and 55% for those in the BOC + PR-RGT arm, respectively. Therefore, adding a protease inhibitor clearly helps boost SVR rates for these patients with difficult-to-treat infections.
This was the tela ad hoc study
The largest improvements in response, however, were observed in patients with the CT and TT alleles – the addition of telaprevir doubled and even tripled SVR rates, Dr. Jacobson said. SVR rates in the CT group reached 71% with 12-week telaprevir plus PR, 57% with 8-week telaprevir plus PR, and 25% with PR alone. SVR rates in the TT group were 73%, 59% and 23%, respectively.
'From Merck:
IL28B genotype helped predict likelihood of treatment response
In pre-specified analyses of the pivotal Phase III studies, researchers found that IL28B status (CC, CT or TT) was a strong baseline predictor of viral response at treatment week 4, week 8 and SVR among patients receiving VICTRELIS. Among those carrying the CC gene allele, 89 percent of treatment-naïve patients and 82 percent of treatment-failure patients had an early response, defined by undetectable virus (HCV-RNA) at treatment week 8, and were eligible for a shorter duration of therapy. Among those with the less favorable gene allele (CT or TT), 52 percent of treatment-naïve patients and 48 percent of treatment-failure patients had an early response and were eligible for a shorter duration of therapy. The analyses also showed that response after the 4-week lead-in was a stronger predictor of SVR than any single baseline variable, including IL28B status.
http://www.merck.com/newsroom/news-release-archive/research-and-development/2011_0331a.html